Document:

ROYALTY CONVERSION AGREEMENT 

 

THIS ROYALTY CONVERSION AGREEMENT
(this “Agreement”), dated as of March 5, 2012, by and among Arrayit Corporation, a Nevada corporation, (“Arrayit”),
Ovarian Cancer Testing, LLP, a Nevada limited liability limited partnership (the “Partnership”) and Arrayit Diagnostics,
a Nevada corporation, (the “Company”) and the partners listed on Schedule I attached hereto (individually, a “Royalty
holder” or collectively “Royalty holders”). Arrayit, Ovarian, the Partnership, the Company and the Royal holders
and individually referred to as a “Party” and collectively as the “Parties.”

 

WITNESSETH: 

 

WHEREAS, the Parties are executing
and delivering this Agreement in reliance upon an exemption from securities registration under Section 4(2), Rule 506 of Regulation
D, or any or all such exemptions as promulgated by the U.S. Securities and Exchange Commission (the “SEC”) under the
Securities Act of 1933, as amended (the “1933 Act”);

 

WHEREAS, the Royalty holders are
the record and beneficial owners of a partnership interest in the Partnership. The Partnership, in turn, entered into a royalty
agreement, date June 30, 2009 with Arrayit Diagnostics (Ovarian), Inc., a Nevada corporation, (“Ovarian”), at the time
a wholly owned subsidiary of Diagnostics, Inc.;

 

WHEREAS, effective May 23, 2011,
Arrayit Diagnostics (Ovarian), Inc. was merged with and into Arrayit Diagnostics, Inc. resulting in Diagnostics becoming obligated
for payment of the Royalty;

 

WHEREAS, the parties desire that,
upon the terms and subject to the conditions contained herein, the Company shall issue to the Royalty holders as provided herein,
and the Royalty holders shall accept the Company's common stock, par value $0.001 (the “Conversion Shares”) in conversion
and full satisfaction of the Royalty;

 

WHEREAS, no commission or other remuneration
will be paid or given, directly or indirectly, in connection with the conversion or redemption of the Royalty;

 

WHEREAS, contemporaneously with the
execution and delivery of this Agreement, the Company is executing and delivering Irrevocable Transfer Agent Instructions substantially
in the form attached hereto as Exhibit A (the “Irrevocable Transfer Agent Instructions”); and

 

NOW, THEREFORE, in consideration
of the mutual covenants and other agreements contained in this Agreement the Parties hereby agree as follows:

 

1. CONVERSION OF ROYALTY.

 

(a) Conversion of Royalty. Subject
to the satisfaction (or waiver) of the terms and conditions of this Agreement, each Royalty elects to convert and the Company agrees
to exchange and issue to each Royalty holder Conversion Shares. The number of shares of Conversion Stock that the Royalty holder
shall receive at Closing is set out on Schedule I hereto.

 

(b) Closing Date. The Closing of
the issuance and sale of Conversion Shares on conversion of the Royalty shall take place at 10:00 a.m. Central Standard Time on
the fifth (5th) business day following the date hereof, subject to notification of satisfaction of the conditions to the Closing
set forth herein and in Sections 6 and 7 below (or such later date as is mutually agreed to by the Company and the Royalty holders
(the “Closing Date”),.

 

    	 

    	 

    

 

2. ROYALTY HOLDER'S REPRESENTATIONS AND WARRANTIES.

 

Each Royalty holder represents and warrants,
severally and not jointly, that:

 

(a) Investment Purpose. Each Royalty
holder acquired the Royalty and, upon conversion of the Royalty, the Royalty holder will acquire the Conversion Shares then issuable,
for its own account. Royalty holders may dispose of the Conversion Shares at any time in accordance with the exemption from registration
in Rule 144 of the 1933 Act covering such Conversion Shares or another available exemption under the 1933 Act.

 

(b) Investor Status. Each Royalty
holder is an “Accredited Investor” as that term is defined in Rule 501(a) of Regulation D and is not an “Affiliate”
as that term is defined in Rule 501(b) of Regulation D of the 1933 Act.

 

(c) Reliance on Exemptions. Each
Royalty holder understands that the Conversion Shares are being offered and sold to it in reliance on specific exemptions from
the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the
truth and accuracy of, and such Royalty holder's compliance with, the representations, warranties, agreements, acknowledgments
and understandings of such Royalty holder set forth herein in order to determine the availability of such exemptions and the eligibility
of such Royalty holder to acquire such securities.

 

(d) Information. Each Royalty holder
and its advisors (and his or, its counsel), if any, have been furnished with all materials relating to the business, finances and
operations of the Company and information he deemed material to making an informed investment decision regarding his purchase of
the Conversion Shares, which have been requested by such Royalty holder. Each Royalty holder and its advisors, if any, have been
afforded the opportunity to ask questions of the Company and its management. Neither such inquiries nor any other due diligence
investigations conducted by such Royalty holder or its advisors, if any, or its representatives shall modify, amend or affect such
Royalty holder's right to rely on the Company's representations and warranties contained in Section 3 below. Each Royalty holder
understands that its investment in the Conversion Shares involves a high degree of risk. Each Royalty holder is in a position regarding
the Company, which, based upon employment, family relationship or economic bargaining power, enabled and enables such Royalty holder
to obtain information from the Company in order to evaluate the merits and risks of this investment. Each Royalty holder has sought
such accounting, legal and tax advice, as it has considered necessary to make an informed investment decision with respect to its
acquisition of the Conversion Shares.

 

(e) No Governmental Review. Each
Royalty holder understands that no United States federal or state agency or any other government or governmental agency has passed
on or made any recommendation or endorsement of the Conversion Shares, or the fairness or suitability of the investment in the
Conversion Shares, nor have such authorities passed upon or endorsed the merits of the offering of the Conversion Shares.

 

(f) Issuance and Transfer or Resale.
Each Royalty holder understands that (i) issuance of the Conversion Shares has not been and are not being registered under the
1933 Act or any state securities laws in reliance on the exemption from such registration in Section 4(2)) of the 1933 Act and
Regulation D thereunder, (ii) any sale, assignment or transfer by the Royalty holder may be made pursuant to the exemption from
such registration in Rule 144 of the 1933 Act; (ii) that any sale of such securities made in reliance on Rule 144 under the 1933
Act (or a successor rule thereto) (“Rule 144”) will be made only in accordance with the terms of Rule 144 and further,
if Rule 144 is not applicable, any resale of such securities under circumstances in which the seller (or the person through whom
the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) will comply with some other exemption
under the 1933 Act or the rules and regulations of the SEC thereunder; and (iv) neither the Company nor any other person is under
any obligation to register such securities under the 1933 Act or any state securities laws or to comply with the terms and conditions
of any exemption thereunder.

 

    	Page 2

    	 

    

 

(g) Legends. Each Royalty holder
understands that the certificates representing the Conversion Shares shall bear the customary restrictive legend and stop transfer
orders shall be placed against transfer of such stock certificates.

 

(h) Authorization, Enforcement. This
Agreement has been duly and validly authorized, executed and delivered on behalf of such Royalty holder and is a valid and binding
agreement of such Royalty holder enforceable in accordance with its terms, except as such enforceability may be limited by general
principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating
to, or affecting generally, the enforcement of applicable creditors' rights and remedies.

 

(i) Receipt of Documents. Each Royalty
holder and his or its counsel has received and read in their entirety: (i) this Agreement and each representation, warranty and
covenant set forth herein, the Security Agreement and the Irrevocable Transfer Agent Instructions; (ii) all due diligence and other
information necessary to verify the accuracy and completeness of such representations, warranties and covenants; and (iii) answers
to all questions each Royalty holder submitted to the Company regarding an investment in the Company; and each Royalty holder has
relied on the information contained therein and has not been furnished any other documents, literature, memorandum or prospectus.

 

(j) Due Formation of Corporate and Other
Royalty holders. If the Royalty holders is a corporation, trust, partnership or other entity that is not an natural person,
it has been formed and validly exists and has not been organized for the specific purpose of purchasing the Conversion Shares and
is not prohibited from doing so.

 

(k) No Legal Advice From the Company.
Each Royalty holder acknowledges, that it had the opportunity to review this Agreement and the transactions contemplated by this
Agreement with his or its own legal counsel and investment and tax advisors. Each Royalty holder is relying solely on such counsel
and advisors and not on any statements or representations of the Company or any of its representatives or agents for legal, tax
or investment advice with respect to this investment, the transactions contemplated by this Agreement or the securities laws of
any jurisdiction.

 

3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The Company represents and warrants to each of the Royalty holders:

 

(a) Organization and Qualification.
The Company and its subsidiaries are corporations duly organized and validly existing in good standing under the laws of the jurisdiction
in which they are incorporated, and have the requisite corporate power to own their properties and to carry on their business as
now being conducted. Each of the Company and its subsidiaries is duly qualified as a foreign corporation to do business and is
in good standing in every jurisdiction in which the nature of the business conducted by it makes such qualification necessary,
except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the
Company and its subsidiaries taken as a whole.

 

    	Page 3

    	 

    

 

(b) Authorization, Enforcement, Compliance
with Other Instruments. (i) The Company has the requisite corporate power and authority to enter into and perform this Agreement,
the Security Agreement, the Irrevocable Transfer Agent Instructions, and any related agreements, and to issue the Conversion Shares
in accordance with the terms hereof and thereof, (ii) the execution and delivery of this Agreement, the Security Agreement, the
Irrevocable Transfer Agent Instructions (as defined herein) and any related agreements by the Company and the consummation by it
of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Conversion Shares and the
reservation for issuance and the issuance of the Conversion Shares issuable upon conversion of the Royalty, have been duly authorized
by the Company's Board of Directors and no further consent or authorization is required by the Company, its Board of Directors
or its stockholders, (iii) this Agreement, the Security Agreement, the Irrevocable Transfer Agent Instructions and any related
agreements have been duly executed and delivered by the Company, (iv) this Agreement, the Security Agreement, the Irrevocable Transfer
Agent Instructions and any related agreements constitute the valid and binding obligations of the Company enforceable against the
Company in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement
of creditors' rights and remedies. The authorized officer of the Company executing this Agreement, the Security Agreement, the
Irrevocable Transfer Agent Instructions and any related agreements knows of no reason why the Company cannot perform any of the
Company's other obligations under such documents.

 

(c) Capitalization. The authorized
capital stock of the Company consists of 480,000,000 shares of Common Stock, par value $0.001 per share and 20,000,000 shares of
Preferred Stock. As of the date hereof, the Company has approximately 30,000,000 shares of Common Stock issued and outstanding
and 3,000,000 shares of preferred stock issued or outstanding. All of such outstanding shares have been validly issued and are
fully paid and nonassessable. No shares of Common Stock are subject to preemptive rights or any other similar rights or any liens
or encumbrances suffered or permitted by the Company. As of the date of this Agreement, there are no outstanding registration statements
and there are no outstanding comment letters from the SEC or any other regulatory agency. There are no securities or instruments
containing anti-dilution or similar provisions that will be triggered by the issuance of the Conversion Shares as described in
this Agreement.

 

(d) Issuance of Securities. The Conversion
Shares issuable upon conversion of the Royalty have been duly authorized and reserved for issuance. Upon conversion or exercise
in accordance with the terms of this Agreement the Conversion Shares will be duly issued, fully paid and nonassessable.

 

(e) No Conflicts. The execution,
delivery and performance of this Agreement, the Security Agreement, and the Irrevocable Transfer Agent Instructions by the Company
and the consummation by the Company of the transactions contemplated hereby will not (i) result in a violation of the Articles
of Incorporation, any certificate of designations of any outstanding series of preferred stock of the Company or the By-laws or
(ii) conflict with or constitute a default (or an event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which the Company or any of its subsidiaries is a party, or result in a violation of any law, rule, regulation, order, judgment
or decree (including federal and state securities laws and regulations and the rules and regulations of Pink Sheets LC on which
the Common Stock is quoted) applicable to the Company or any of its subsidiaries or by which any property or asset of the Company
or any of its subsidiaries is bound or affected. Neither the Company nor its subsidiaries is in violation of any term of or in
default under its Articles of Incorporation or By-laws or their organizational charter or by-laws, respectively, or any material
contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or regulation
applicable to the Company or its subsidiaries. The business of the Company and its subsidiaries is not being conducted, and shall
not be conducted in violation of any material law, ordinance, or regulation of any governmental entity. Except as specifically
contemplated by this Agreement and as required under the 1933 Act and any applicable state securities laws, the Company is not
required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency
in order for it to execute, deliver or perform any of its obligations under or contemplated by this Agreement in accordance with
the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which the Company is required to obtain
pursuant to the preceding sentence have been obtained or effected on or prior to the date hereof. The Company and its subsidiaries
are unaware of any facts or circumstance, which might give rise to any of the foregoing.

 

    	Page 4

    	 

    

 

(f) Absence of Litigation. There
is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory
organization or body pending against or affecting the Company, the Common Stock or any of the Company's subsidiaries, wherein an
unfavorable decision, ruling or finding would have a material adverse effect on the transactions contemplated hereby (ii) adversely
affect the validity or enforceability of, or the authority or ability of the Company to perform its obligations under, this Agreement
or any of the documents contemplated herein, or (iii) have a material adverse effect on the business, operations, properties, financial
condition or results of operations of the Company and its subsidiaries taken as a whole.

 

(g) Acknowledgment Regarding Royalty
holder's Purchase of the Conversion Shares. The Company acknowledges and agrees that: (i) no commission or other remuneration
will be paid or given, directly or indirectly, in connection with the conversion or redemption of the Royalty, (ii) the Royalty
holders is acting solely in the capacity of an arm's length purchaser with respect to this Agreement and the transactions contemplated
hereby, (iii) the Royalty is a bona fide obligation of the Company and was originally entered into more than two (2) years prior
to the date hereof. The Company further acknowledges that the Royalty holders is not acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any advice
given by the Royalty holders or any of their respective representatives or agents in connection with this Agreement and the transactions
contemplated hereby is merely incidental to such Royalty holder's purchase of the Conversion Shares. The Company further represents
to the Royalty holder that the Company's decision to enter into this Agreement has been based solely on the independent evaluation
by the Company and its representatives.

 

(h) No General Solicitation. Neither
the Company, nor any of its affiliates, nor any person acting on its or their behalf, has engaged in any form of general solicitation
or general advertising (within the meaning of Regulation D under the 1933 Act) in connection with the offer or sale of the Conversion
Shares.

 

(i) No Integrated Offering. Neither
the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the
Conversion Shares under the 1933 Act or cause this offering of the Conversion Shares to be integrated with prior offerings by the
Company for purposes of the 1933 Act.

 

4. COVENANTS.

 

(a) Best Efforts. Each party shall
use its best efforts timely to satisfy each of the conditions to be satisfied by it as provided in Sections 6 and 7 of this Agreement.

 

(b) Form D. The Company agrees to
file a Form D with respect to the Conversion Shares as required under Regulation D and to provide a copy thereof to each Royalty
holder promptly after such filing. The Company shall, on or before the Closing Date, take such action as the Company shall reasonably
determine is necessary to qualify the Conversion Shares, or obtain an exemption for the Conversion Shares for sale to the Royalty
holders at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of the states of the
United States, and shall provide evidence of any such action so taken to the Royalty holders on or prior to the Closing Date.

 

(c) Reservation of Shares. The Company
shall take all action reasonably necessary to at all times have authorized, and reserved for the purpose of issuance, such number
of shares of Common Stock as shall be necessary to effect the issuance of the Conversion Shares. If at any time the Company does
not have available such shares of Common Stock as shall from time to time be sufficient to effect the conversion of all of the
Conversion Shares of the Company shall call and hold a special meeting of the shareholders within sixty (60) days of such occurrence,
for the sole purpose of increasing the number of shares authorized. The Company's management shall recommend to the shareholders
to vote in favor of increasing the number of shares of Common Stock authorized. Management shall also vote all of its shares in
favor of increasing the number of authorized shares of Common Stock.

 

    	Page 5

    	 

    

 

(d) Listings or Quotation. The Company
will use its commercially reasonable best efforts to qualify the Company’s Common Stock for quotation on the Over-The-Counter
Bulletin Board (“OTCBB”) or other over-the-counter market.

 

(e) Fees and Expenses. Each of the
Company and the Royalty holders shall pay all costs and expenses incurred by such party in connection with the negotiation, investigation,
preparation, execution and delivery of this Agreement, the Security Agreement and the Irrevocable Transfer Agent Instructions.

 

(f) Transfer Agent. The Company covenants
and agrees that, in the event that the Company's agency relationship with the transfer agent should be terminated for any reason
prior to a date which is two (2) years after the Closing Date, the Company shall immediately appoint a new transfer agent and shall
require that the new transfer agent execute and agree to be bound by the terms of the Irrevocable Transfer Agent Instructions (as
defined herein).

 

5. TRANSFER AGENT INSTRUCTIONS.

 

The Company shall issue the Irrevocable
Transfer Agent Instructions to its transfer agent irrevocably appointing Sonfield & Sonfield as its agent for purpose of having
certificates issued, registered in the name of the Royalty holders or its respective nominee(s), for the Conversion Shares representing
such amounts of Royalty as specified from time to time by the Royalty holders to the Company upon conversion of the Royalty, for
interest owed pursuant to the Royalty, and for any and all Liquidated Damages. The Company shall instruct the Transfer Agent that
such certificates shall bear the customary restrictive legend. The Company warrants that no instruction other than the Irrevocable
Transfer Agent Instructions referred to in this Section 5, will be given by the Company to its transfer agent and that the Conversion
Shares shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement.
Nothing in this Section 5 shall affect in any way the Royalty holder's obligations and agreement to comply with all applicable
securities laws upon resale of Conversion Shares. The Company acknowledges that a breach by it of its obligations hereunder will
cause irreparable harm to the Royalty holder by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly,
the Company acknowledges that the remedy at law for a breach of its obligations under this Section 5 will be inadequate and agrees,
in the event of a breach or threatened breach by the Company of the provisions of this Section 5, that the Royalty holders shall
be entitled, in addition to all other available remedies, to an injunction restraining any breach and requiring immediate issuance
and transfer, without the necessity of showing economic loss and without any bond or other security being required.

 

6. CONDITIONS TO THE COMPANY'S OBLIGATION TO SELL. 

 

The obligation of the Company hereunder
to issue and sell the Conversion Shares to the Royalty holders at the Closings is subject to the satisfaction, at or before the
Closing Dates, of each of the following conditions, provided that these conditions are for the Company's sole benefit and may be
waived by the Company at any time in its sole discretion:

 

(a) Execution of Agreements. Each
Royalty holder shall have executed this Agreement and delivered the same to the Company.

 

(b) Representations and Warranties.
The representations and warranties of the Royalty holders shall be true and correct in all material respects as of the date when
made and as of the Closing Dates as though made at that time (except for representations and warranties that speak as of a specific
date), and the Royalty holders shall have performed, satisfied and complied in all material respects with the covenants, agreements
and conditions required by this Agreement to be performed, satisfied or complied with by the Royalty holders at or prior to the
Closing Dates.

 

    	Page 6

    	 

    

 

7. CONDITIONS TO THE ROYALTY HOLDER'S OBLIGATION TO PURCHASE.

 

The obligation of the Royalty holders hereunder
to convert the Royalty at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions:

 

(a) Execution of Agreements. The
Company shall have executed this Agreement, the Security Agreement and the Irrevocable Transfer Instructions and delivered the
same to the Royalty holders.

 

(b) Representations and Warranties.
The representations and warranties of the Company shall be true and correct in all material respects (except to the extent that
any of such representations and warranties is already qualified as to materiality in Section 3 above, in which case, such representations
and warranties shall be true and correct without further qualification) as of the date when made and as of the Closing Dates as
though made at that time (except for representations and warranties that speak as of a specific date) and the Company shall have
performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement
to be performed, satisfied or complied with by the Company at or prior to the Closing Dates.

 

(d) Delivery of Shares. The Company
shall have delivered to the Royalty holders the Conversion Shares in the respective amounts set forth opposite each Royalty holders
name in Appendix I.

 

(e) Reservation of Shares. As of
the Closing Date, the Company shall have reserved out of its authorized and unissued Common Stock, solely for the purpose of effecting
the conversion of the Royalty, shares of Common Stock to effect the conversion of all of the unpaid balance of the Royalty then
outstanding.

 

(f) Transfer Agent Instructions.
The Irrevocable Transfer Agent Instructions, in form and substance satisfactory to the Royalty holder, shall have been delivered
to the Company's transfer agent.

 

8. INDEMNIFICATION.

 

Indemnification of Company. In consideration
of the Company's execution and delivery of this Agreement, and in addition to all of the Royalty holder's other obligations under
this Agreement, the Royalty holder shall defend, protect, indemnify and hold harmless the Company and all of its officers, directors,
employees and agents (including, without limitation, those retained in connection with the transactions contemplated by this Agreement)
(collectively, the “Company Indemnitees”) from and against any and all Indemnified Liabilities incurred by the Indemnitees
or any of them as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty
made by the Royalty holders in this Agreement, , instrument or document contemplated hereby or thereby executed by the Royalty
holder, (b) any breach of any covenant, agreement or obligation of the Royalty holders contained in this Agreement, or any other
certificate, instrument or document contemplated hereby or thereby executed by the Royalty holder, or (c) any cause of action,
suit or claim brought or made against such Company Indemnitee based on material misrepresentations or due to a material breach
and arising out of or resulting from the execution, delivery, performance or enforcement of this Agreement or any other instrument,
document or agreement executed pursuant hereto by any of the Company Indemnities. To the extent that the foregoing undertaking
by each Royalty holder may be unenforceable for any reason, each Royalty holder shall make the maximum contribution to the payment
and satisfaction of each of the Indemnified Liabilities, which is permissible under applicable law.

 

    	Page 7

    	 

    

 

9. GOVERNING LAW: MISCELLANEOUS. 

 

(a) Governing Law. This Agreement
shall be governed by and interpreted in accordance with the laws of the State of Texas without regard to the principles of conflict
of laws. The parties further agree that any action between them shall be heard in Harris County, Texas, and expressly consent to
the jurisdiction and venue of the District Court of Harris County Texas, sitting in Houston, Texas and the United States District
Court for the Southern District of Texas sitting in Houston, Texas for the adjudication of any civil action asserted pursuant to
this Paragraph.

 

(b) Counterparts. This Agreement
may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the other party. In the event any signature page is
delivered by facsimile transmission, the party using such means of delivery shall cause an additional original executed signature
pages to be physically delivered to the other party within five (5) days of the execution and delivery hereof.

 

(c) Headings. The headings of this
Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

 

(d) Severability. If any provision
of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the
validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision
of this Agreement in any other jurisdiction.

 

(e) Entire Agreement, Amendments.
This Agreement supersedes all other prior oral or written agreements between the Royalty holders, the Company, their affiliates
and persons acting on their behalf with respect to the matters discussed herein, and this Agreement and the instruments referenced
herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically
set forth herein or therein, neither the Company nor any Royalty holder makes any representation, warranty, covenant or undertaking
with respect to such matters. No provision of this Agreement may be waived or amended other than by an instrument in writing signed
by the party to be charged with enforcement.

 

(f) Notices. Any notices, consents,
waivers, or other communications required or permitted to be given under the terms of this Agreement must be in writing and will
be deemed to have been delivered (i) upon receipt, when delivered personally; (ii) upon confirmation of receipt, when sent by facsimile;
(iii) three (3) days after being sent by U.S. certified mail, return receipt requested, or (iv) one (1) day after deposit with
a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses
and facsimile numbers for such communications shall be:

 

if to the Company:

 

Arrayit Diagnostics

1950 Cinnamon Teal Drive

Redmond, Oregon 97756 (408) 744-1331

Attn: Mr. John Howell,

President & CEO

Phone: (408) 744-1331

 

    	Page 8

    	 

    

 

if to the Transfer Agent:

 

ClearTrust, LLC

16540 Pointe Village Dr., Suite 206

Lutz, FL 33558

Facsimile (813) 388-4549

 

If to the Royalty holders, to its address
and facsimile number on Schedule I, with copies to the Royalty holder's counsel as set forth on Schedule I. Each party shall provide
five (5) days' prior written notice to the other party of any change in address or facsimile number.

 

(g) Successors and Assigns. This
Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns. The Parties
holder shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party
hereto.

 

(h) No Third Party Beneficiaries.
This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is
not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

(i) Survival. Unless The representations
and warranties of the Company and the Royalty holders contained in Sections 2 and 3, the agreements and covenants set forth in
Sections 4, 5 and 9, and the indemnification provisions set forth in Section 8, shall survive the Closing for a period of two (2)
years following the date on which the Royalty is converted in full. The Royalty holders shall be responsible only for its own representations,
warranties, agreements and covenants hereunder.

 

(j) Publicity. The Company and the
Royalty holders shall have the right to approve, before issuance any press release or any other public statement with respect to
the transactions contemplated hereby made by any party; provided, however, that the Company shall be entitled, without the prior
approval of the Royalty holders, to issue any press release or other public disclosure with respect to such transactions required
under applicable securities or other laws or regulations (the Company shall use its best efforts to consult the Royalty holders
in connection with any such press release or other public disclosure prior to its release and Royalty holders shall be provided
with a copy thereof upon release thereof).

 

(k) Further Assurances. Each party
shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such
other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the
intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(l) Termination. In the event that
the Closing shall not have occurred with respect to the Royalty holders on or before five (5) business days from the date hereof
due to the Company's or the Royalty holder's failure to satisfy the conditions set forth in Sections 6 and 7 above (and the non-breaching
party's failure to waive such unsatisfied condition(s)), the non-breaching party shall have the option to terminate this Agreement
with respect to such breaching party at the close of business on such date without liability of any party to any other party.

 

(m) No Strict Construction. The language
used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of
strict construction will be applied against any party.

 

    	Page 9

    	 

    

 

IN WITNESS WHEREOF, the Parties have
caused this Royalty Conversion Agreement to be duly executed as of the date first written above.

 

	COMPANY	 	ROYALTY HOLDERS
	 	 	 
	ARRAYIT DIAGNOSTICS, INC.	 	 
	 	      	John R. Lester
	By:	/s/ John Howell	 	 
	 	John Howell, President	 	 
		 	John Weisner
	ARRAYIT CORPORATION	 	 
	 	 	 
	By:	/s/ Rene A. Schena	 	Timothy Phelan
	 	Rene A. Schena, Chief Executive Officer	 	 
	 	 	 	 
	 	 	Jerry W. Neel Jr.
	 	Dr. Sylvin Mayford Griffin	 	 
	 	 	OVARIAN CANCER TESTING LLLP
	 	 	
	 	Palmer Melton	 	By:	 
	 	 	 	John R. Lester, General Partner
	 	 		 
	 	Talley Melton	 	 	  

 

    	Page 10

    	 

    

 

SCHEDULE I

 

ROYALTY HOLDERS

 

	Name and Address of Royalty holder	 	Number of Conversion Shares	 
	 	 	 	 
	John R. Lester 
710 N Post Oak Rd Suite 120, 
Houston, Texas 77024 3847	 	 	25,000	 
	John Weisner	 	 	50,000	 
	Timothy Phelan	 	 	50,000	 
	Jerry W. Neel Jr.	 	 	25,000	 
	Dr. Sylvin Mayford Griffin	 	 	10,000	 
	Palmer and Talley Melton	 	 	25,000	 
	Total	 	 	210,000	 

 

    	Page 11

    	 

    

 

	EXHIBIT A
	Arrayit Diagnostics

1127 Broadway St NE, Suite 316    Salem, Oregon 97301

 

September ___, 2007

 

ClearTrust, LLC

16540 Pointe Village Dr., Suite 206

Lutz, FL 33558

 

Ladies and Gentlemen:

 

Arrayit Diagnostics,
a Nevada corporation (the “Company”), and certain investors (the “Royalty holders”) have entered into a
Royalty Conversion Agreement dated as of March ___, 2012 (the “Agreement”) providing for the issuance of shares of
common stock of the Company (“Conversion Shares”) in exchange and conversion of outstanding royalty interests (the
“Royalty”).

 

You are hereby irrevocably
authorized and instructed to issue 185,000 shares of Common Stock in accordance with the Schedule I attached.

 

The Company hereby confirms
to you that the shares have not been registered under the Securities Act of 1933 or otherwise. Therefore the shares shall be issued
in certificated form with the customary restrective legend to restrict the transfer of the shares, and you should record all stop-transfer
instructions relating to such shares.

 

The Royalty holders are
intended to be and are third party beneficiaries hereof, and no amendment or modification to the instructions set forth herein
may be made without the consent of such Royalty holders.

 

Very truly yours,

 

ARRAYIT DIAGNOSTICS

 

	/s/ John Howell	 
	John Howell, President	 

 

    	Page 12ROYALTY PURCHASE AGREEMENT

 

THIS AGREEMENT is made and entered into
this first day of March, 2012 by and between Recap Marketing and Consulting, LLP, 12000 Westheimer Suite 340, Houston, Texas 77077,
(“Seller”) and Arrayit Diagnostics, Inc. Nevada corporation (“Purchaser”).

 

The Seller is the record owner and holder
of 20% royalties of the sales of Arrayit Diagnostic’s ovarian cancer test.

 

In consideration of the mutual agreements
contained in this document, it is hereby agreed as follows:

 

		1.	PURCHASE AND SALE: Subject to the terms and conditions stated
in this Agreement, the Seller shall sell, and relinquish all rights to the Purchaser its 20% royalty rights, referenced in the
Recap Marketing & Consulting LLP’s consulting agreement of August 11, 2009. All other parts of the agreement whether
consideration or consulting remain intact.

		2.	AMOUNT AND PAYMENT OF PURCHASE PRICE. The total consideration
and method of payment thereof are fully set out in Exhibit “A” attached to this Agreement and incorporated herein for
all purposes as if set forth in full.

		3.	REPRESENTATIONS AND WARRANTIES OF SELLER. The seller is a
Limited Liability Partnership that is duly organized, validly existing and in good standing under the laws of the State of Texas
and has the power and authority to carry on its business as it is now being conducted. The Seller is an accredited investor. Upon
payment of the consideration for the royalties, Seller shall have no further right or interest in any royalties of any kind in
the sales of Arrayit Diagnostics, Inc.

		4.	REPRESENTATIONS AND WARRANTIES OF PURCHASER. There is no liability,
and no causes of action between the parties once the purchaser has paid.

		5.	REPRESENTATIONS AND WARRANTIES OF SELLER AND PURCHASER. Seller
and Purchaser hereby represent and warrant that there has been no act or omission by Seller, Purchaser or the Corporation which
would give rise to any valid claim against any of the parties hereto for a brokerage commission, finder’s fee, or other like
payment in connection with the transactions contemplated hereby.

		6.	GENERAL PROVISIONS. (a) Entire Agreement. This Agreement constitutes
the entire Agreement and supersedes all prior agreements and understandings, oral and written, between the parties hereto with
respect to the subject matter hereof. (b) Governing Law. This agreement shall be governed by Texas Law.

 

	Seller:  Hunter Carr, General Partner	 	Buyer:                      
	 	 	 
		 	 
	 	 	 
	Recap Marketing and Consulting, LLP

12000 Westheimer Suite 340	 	By:	 
	Houston, Texas 77077	 	Arrayit Diagnostics, Inc.
	 	 	John Howell, CEO
	 	 	1950 Cinnamon Teal Dr.
	 	 	Redmond, Or 97756
	 	 	 
	 	 	 
	 	 	 
	 	 	Email:   jsamarketing@live.com

 

    	 

    	 

    

 

EXHIBIT “A”

 

AMOUNT AND PAYMENT OF PURCHASE PRICE

 

Consideration: As total consideration for
the purchase of the 20% Royalty right, pursuant to this Agreement, the Purchaser shall pay to the Seller the sum of 385,000 shares
of common stock of Arrayit Diagnostics, Inc. as the full purchase price for the Royalty rights.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]